| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.067 | 0.07 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.07 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | -0.069 | 0.07 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.07 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.07 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.063 | 0.07 |
| mRNA | apicidin | CTRPv2 | pan-cancer | AAC | -0.057 | 0.07 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.066 | 0.07 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.092 | 0.07 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.054 | 0.07 |